scholarly article | Q13442814 |
P50 | author | Michael T Lotze | Q89121415 |
Steven Rosenberg | Q2347448 | ||
P2093 | author name string | Rudikoff S | |
Nordan RP | |||
Mulé JJ | |||
Jablons DM | |||
McIntosh JK | |||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 162-167 | |
P577 | publication date | 1989-07-01 | |
P1433 | published in | Journal of Immunology | Q3521441 |
P1476 | title | In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice | |
P478 | volume | 143 |
Q34247741 | Adaptation to bacterial lipopolysaccharide controls lipopolysaccharide-induced tumor necrosis factor production in rabbit macrophages |
Q36350671 | Antitumor activity of recombinant interleukin 6 in mice |
Q36631630 | Changes in Mobility of the Golden Hamster with Induction of an IL-1-Induced Arthritis |
Q42475817 | Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer |
Q34132434 | Dietary lipids and calorie restriction affect mammary tumor incidence and gene expression in mouse mammary tumor virus/v-Ha-ras transgenic mice |
Q68499138 | Differential augmentation of in vivo natural killer cytotoxicity in normal primates with recombinant human interleukin-1 and granulocyte-macrophage colony-stimulating factor |
Q35602921 | Evidence for the involvement of interleukin 6 in experimental cancer cachexia |
Q28533317 | Functional characterization of detergent-decellularized equine tendon extracellular matrix for tissue engineering applications |
Q34288655 | IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation |
Q71739906 | Interaction of interleukin-6, tumour necrosis factor and interleukin-1 during Listeria infection |
Q41807421 | Interleukin-1 and tumour necrosis factor induce hepatic haem oxygenase. Feedback regulation by glucocorticoids |
Q35602202 | Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia |
Q39232767 | Interleukin-2 in cancer treatment: disappointing or (still) promising? A review |
Q35993599 | Interleukin-6 serum level and monocyte production in head and neck cancer |
Q74397599 | Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker |
Q42082745 | Mesangial cell-matrix interactions. Effects on mesangial cell growth and cytokine secretion |
Q35945218 | Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors |
Q40754979 | Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity |
Q37803895 | Rationale for immunotherapy of renal cell carcinoma |
Q36231011 | Role of interleukin 6 (IL-6) in protection from lethal irradiation and in endocrine responses to IL-1 and tumor necrosis factor |
Q36761832 | Syndecan-1 is an in vivo suppressor of Gram-positive toxic shock |
Q39830126 | The decrease in nonsplenic interleukin-6 (IL-6) production after splenectomy indicates the existence of a positive feedback loop of IL-6 production during endotoxemia in dogs. |
Q72919717 | The effects of a biological response modifier, OK-432, on tumor-induced alterations in the host metabolism |
Search more.